Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Geode Capital Management LLC lessened its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 0.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,661,878 shares of the company’s stock after selling 20,450 shares during the period. Geode Capital Management LLC owned about 1.80% of Adaptive Biotechnologies worth $13,632,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptive Biotechnologies during the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Adaptive Biotechnologies during the third quarter valued at approximately $34,000. MQS Management LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $36,000. Rothschild Investment LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $36,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $49,000. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ADPT. BTIG Research boosted their price objective on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th.

Adaptive Biotechnologies Stock Down 2.9 %

Shares of NASDAQ:ADPT opened at $6.11 on Tuesday. The company has a market capitalization of $901.71 million, a price-to-earnings ratio of -4.56 and a beta of 1.49. Adaptive Biotechnologies Co. has a 52 week low of $2.28 and a 52 week high of $7.07. The firm has a 50 day moving average of $5.68 and a 200 day moving average of $4.80.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.